US Stock Insider Trading | Regenxbio disclosed 1 insider trading activity detail on March 12

K-LinePoet · 2026-04-09T12:46:06+00:00

Regenxbio disclosed on March 12, 2026, that executive PAKOLA STEVE sold 5,124 shares on March 10, with a total transaction amount of $53k. In recent years, the company's insiders have conducted multiple transactions involving stock trading. Regenxbio is a biotechnology company focused on gene therapy, dedicated to developing therapeutic products using AAV vectors.

K-LinePoet

2026-04-09 12:46:06

Abstract generation in progress

On March 12, 2026, Regenxbio (RGNX) disclosed a single insider trading transaction. Executive PAKOLA STEVE sold 5,124 shares on March 10, 2026.

【Recent Insider Trades】

Disclosure Date	Position	Name	Trade Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 12, 2026	Executive	PAKOLA STEVE	March 10, 2026	Sell	5,124	10.35	$53k
February 3, 2026	Executive	PAKOLA STEVE	February 1, 2026	Sell	5,267	11.16	$58.8k
February 3, 2026	Executive	Christmas Patrick J.	February 1, 2026	Sell	4,700	11.16	$52.5k
January 29, 2026	Director	Mills Kenneth T.	January 27, 2026	Buy	225k	13.09	$2.95M
January 29, 2026	Director	Mills Kenneth T.	January 27, 2026	Sell	221.8k	13.41	$2.97M
January 6, 2026	Executive	Christmas Patrick J.	January 2, 2026	Sell	9,793	14.40	$141k
January 6, 2026	Executive	Malzahn Craig	January 2, 2026	Sell	1,238	14.40	$17.8k
January 6, 2026	Executive	PAKOLA STEVE	January 2, 2026	Sell	18.2k	14.40	$262.8k
January 6, 2026	Director	Simpson Curran	January 2, 2026	Sell	18.6k	14.40	$267.2k
October 10, 2025	Director	Simpson Curran	October 9, 2025	Sell	20.8k	12.62	$262.6k

【Company Information】

Regenxbio Inc. was founded on July 16, 2008. The company is a leading biotechnology firm focused on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapies. In AAV gene therapy, viral genes are removed from AAV (a small, non-pathogenic cold virus) to construct a biological delivery tool called a vector. Then, therapeutic gene sequences are inserted into the vector, forming a recombinant vector. The company owns a proprietary AAV gene delivery platform, which includes exclusive rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9, and AAVrh10. The company’s mission is to develop and commercialize in vivo gene therapy products—administered directly into the body—based on its NAV technology platform, to improve the lives of patients suffering from serious diseases with significant unmet medical needs.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.